

Cover Story
It's possible that molecular testing is doing a lot of good, pinpointing cancer therapies that are most likely (or least likely) to work.
In Brief


Trending Stories
- On Capitol Hill, NIH gets congressional support and RFK Jr. gets slammed
- Jonathan Mahler on his front-page story in the NYT Magazine on Trump’s deliberate dismantling of America’s War on Cancer
- The Directors: Ben Ho Park and Suresh Ramalingam discuss tough times, uncertainty, and resilience
“If you’re going to be an oncologist, we look at the glass 5% full, not 95% empty.” - After stormy Senate hearing, Trump offers tepid support for RFK Jr. while Kennedy family members call for his ouster
- Reflections of a cancer scientist
Maintaining the pace of novel technologies will lead to more efficient and less toxic medicines - Bonnie Addario, lung cancer survivor and advocate, dies at 77